Two takes from the Chair and the CEO."The next step for this...

Two takes from the Chair and the CEO.

"The next step for this program is to complete an engineering run (manufacturing at commercial scale) and then complete GLP toxicology studies. These activities have not been initiated as the Company conserves cash in preparation for its PAT-DX1 clinical trial, but stand ready to be activated when additional capital is available to the Company or we enter into
a development partnership with a third party."
"Strong industry deal flow, experienced deal-makers and drug developers."

On the Chair's appointment.
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “On behalf of the
Board, I am delighted to welcome Dr Gittleson to the Patrys Board as Chairman, and look forward to
working with her as we evolve into a clinical-stage company. Charmaine’s expertise and networks will
be invaluable to us as we initiate the clinical development of PAT-DX1 and seek to expand the
opportunities for PAT-DX1 and PAT-DX3 through additional programs and partnerships. Charmaine’s
strong interpersonal skills will help shape the Company as we move to the next, exciting stage of our
growth.
Not a coincidence!!!..